

## ASX ANNOUNCEMENT MARKET RELEASE

10 November 2023

### RELEASE OF SECURITIES FROM ESCROW

Artrya Limited (ASX: AYA), ("Artrya" or the "Company"), a medical technology company focused on commercialising its patented artificial intelligence platform that detects, diagnoses and helps address coronary artery disease, advises that in accordance with ASX Listing Rule 3.10A, the following securities will be released from ASX mandatory escrow on 26 November 2023.

Class of Securities	Number of Securities	Release Date
Ordinary Shares	15,610,470	26 November 2023
Options (expiry 09/07/2026)	5,500,000	26 November 2023
Options (expiry 23/04/2026)	500,000	26 November 2023
Options (expiry 25/03/2024)	6,000,000	26 November 2023

*This announcement was approved by the CEO.*

#### For further information please contact:

Mathew Regan  
Artrya Limited  
+61 427 427 298  
[investors@artrya.com](mailto:investors@artrya.com)

#### About Artrya

Based in Perth, Australia, Artrya was founded in 2018 with operations starting in early 2019. The Company was listed on the Australian Securities Exchange (ASX: AYA) in 2021.

Artrya is an applied artificial intelligence healthcare company that works alongside clinicians to improve the diagnosis of coronary heart disease and develop a holistic overview of at risk patients. The company has developed deep learning algorithms that predict and prevent acute coronary events.

For more information, see [www.artrya.com](http://www.artrya.com)